288 related articles for article (PubMed ID: 24635522)
1. Fragment-based inhibitor discovery against β-lactamase.
Nichols DA; Renslo AR; Chen Y
Future Med Chem; 2014 Mar; 6(4):413-27. PubMed ID: 24635522
[TBL] [Abstract][Full Text] [Related]
2. β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
Tooke CL; Hinchliffe P; Bragginton EC; Colenso CK; Hirvonen VHA; Takebayashi Y; Spencer J
J Mol Biol; 2019 Aug; 431(18):3472-3500. PubMed ID: 30959050
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of β-lactamase inhibitors.
Jalde SS; Choi HK
J Microbiol; 2020 Aug; 58(8):633-647. PubMed ID: 32720096
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
Mascaretti OA; Danelon GO; Laborde M; Mata EG; Setti EL
Curr Pharm Des; 1999 Nov; 5(11):939-53. PubMed ID: 10539998
[TBL] [Abstract][Full Text] [Related]
5. Resistance to beta-lactam antibiotics: structure and mechanism based design of beta-lactamase inhibitors.
Sandanayaka VP; Prashad AS
Curr Med Chem; 2002 Jun; 9(12):1145-65. PubMed ID: 12052169
[TBL] [Abstract][Full Text] [Related]
6. Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors.
Somboro AM; Osei Sekyere J; Amoako DG; Essack SY; Bester LA
Appl Environ Microbiol; 2018 Sep; 84(18):. PubMed ID: 30006399
[TBL] [Abstract][Full Text] [Related]
7. High-Throughput Virtual Screening, Molecular Dynamics Simulation, and Enzyme Kinetics Identified ZINC84525623 as a Potential Inhibitor of NDM-1.
Rehman MT; AlAjmi MF; Hussain A; Rather GM; Khan MA
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769822
[TBL] [Abstract][Full Text] [Related]
8. Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria.
Davies DT; Everett M
Acc Chem Res; 2021 May; 54(9):2055-2064. PubMed ID: 33788541
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Potential Inhibitor (MCULE-8777613195-0-12) of New Delhi Metallo-β-Lactamase-1 (NDM-1) Using In Silico and In Vitro Approaches.
Muteeb G; Rehman MT; AlAjmi MF; Aatif M; Farhan M; Shafi S
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144666
[TBL] [Abstract][Full Text] [Related]
10. Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium.
Thomson KS; Smith Moland E
Microbes Infect; 2000 Aug; 2(10):1225-35. PubMed ID: 11008112
[TBL] [Abstract][Full Text] [Related]
11. Chromophore-linked substrate (CLS405): probing metallo-β-lactamase activity and inhibition.
Makena A; van Berkel SS; Lejeune C; Owens RJ; Verma A; Salimraj R; Spencer J; Brem J; Schofield CJ
ChemMedChem; 2013 Dec; 8(12):1923-9. PubMed ID: 24166830
[TBL] [Abstract][Full Text] [Related]
12. Interplay between β-lactamases and new β-lactamase inhibitors.
Bush K; Bradford PA
Nat Rev Microbiol; 2019 May; 17(5):295-306. PubMed ID: 30837684
[TBL] [Abstract][Full Text] [Related]
13. Metallo-β-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design.
Wang JF; Chou KC
Curr Top Med Chem; 2013; 13(10):1242-53. PubMed ID: 23647546
[TBL] [Abstract][Full Text] [Related]
14. Active-Site Druggability of Carbapenemases and Broad-Spectrum Inhibitor Discovery.
Torelli NJ; Akhtar A; DeFrees K; Jaishankar P; Pemberton OA; Zhang X; Johnson C; Renslo AR; Chen Y
ACS Infect Dis; 2019 Jun; 5(6):1013-1021. PubMed ID: 30942078
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.
Faheem M; Rehman MT; Danishuddin M; Khan AU
PLoS One; 2013; 8(2):e56926. PubMed ID: 23437273
[TBL] [Abstract][Full Text] [Related]
16. Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach.
Muteeb G; Alsultan A; Farhan M; Aatif M
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209073
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions.
Therrien C; Levesque RC
FEMS Microbiol Rev; 2000 Jul; 24(3):251-62. PubMed ID: 10841972
[TBL] [Abstract][Full Text] [Related]
18. Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors.
Brindisi M; Brogi S; Giovani S; Gemma S; Lamponi S; De Luca F; Novellino E; Campiani G; Docquier JD; Butini S
J Enzyme Inhib Med Chem; 2016; 31(sup1):98-109. PubMed ID: 27121013
[TBL] [Abstract][Full Text] [Related]
19. Class D β-lactamases: a reappraisal after five decades.
Leonard DA; Bonomo RA; Powers RA
Acc Chem Res; 2013 Nov; 46(11):2407-15. PubMed ID: 23902256
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
Liu B; Trout REL; Chu GH; McGarry D; Jackson RW; Hamrick JC; Daigle DM; Cusick SM; Pozzi C; De Luca F; Benvenuti M; Mangani S; Docquier JD; Weiss WJ; Pevear DC; Xerri L; Burns CJ
J Med Chem; 2020 Mar; 63(6):2789-2801. PubMed ID: 31765155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
